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Abstract
Septic infections dysregulate hemostatic pathways, prompting coagulopathy. Nevertheless,
anticoagulant therapies typically fail to protect humans from septic pathology. The data reported
here may help to explain this discrepancy by demonstrating critical protective roles for
coagulation leading to fibrin deposition during host defense against the gram-negative bacterium
Yersinia enterocolitica. After intraperitoneal inoculation with Y. enterocolitica, fibrinogen-
deficient mice display impaired cytokine and chemokine production in the peritoneal cavity and
suppressed neutrophil recruitment. Moreover, both gene-targeted fibrinogen-deficient mice and
wild type mice treated with the anticoagulant coumadin display increased hepatic bacterial burden
and mortality following either intraperitoneal or intravenous inoculation with Y. enterocolitica.
Mice with low tissue factor (TF) activity succumb to yersiniosis with a phenotype similar to
fibrin(ogen)-deficient mice, whereas factor XI (FXI)-deficient mice show wild type levels of
resistance. Mice deficient in plasminogen activator inhibitor-1 (PAI-1) or thrombin activatable
fibrinolysis inhibitor (TAFI) display modest phenotypes, but mice deficient in both PAI-1 and
TAFI succumb to yersiniosis with a phenotype resembling fibrin(ogen)-deficient mice. These
findings demonstrate critical protective roles for the TF-dependent extrinsic coagulation pathway
during host defense against bacteria and caution that therapeutics targeting major thrombin-
generating or anti-fibrinolytic pathways may disrupt fibrin-mediated host defense during gram-
negative sepsis.
Introduction
Hemostatic blood coagulation pathways culminate in the deposition of fibrin, a provisional
extracellular matrix that contributes to blood clotting and wound repair. Fibrin levels are
regulated by fibrin-promoting coagulant pathways and fibrin-degrading fibrinolytic
pathways. During sepsis, a major cause of death in hospitals, hemostasis becomes
unbalanced: up-regulated procoagulant activity is insufficiently balanced by anticoagulation
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and fibrinolysis, prompting disseminated intravascular coagulation (DIC) and fibrin
deposition (1, 2). In addition to promoting ischemia and inflammation, DIC eventually
consumes critical blood-clotting factors, thus contributing to hemorrhage and shock. This
constellation of coagulopathies is difficult to treat and contributes to the high mortality rates
for patients presenting with sepsis (1, 2).
While DIC contributes to septic pathology, coagulation leading to fibrin deposition also can
perform critical protective functions during infection. Mice lacking the capacity to produce
fibrin (e.g. gene-targeted fibrinogen-deficient mice or coumadin-treated wild type mice)
succumb prematurely to infection with Toxoplasma gondii (3). The premature deaths appear
to result from hemorrhage caused by the immune system as it clears this protozoan parasite
from the liver. Likewise, fibrin-deficiency prompts acute hepatic hemorrhage 5 days after
inoculation of mice with Listeria monocytogenes, a gram-positive bacterium (4). Thus,
fibrin-mediated “hemostatic immunity” can be critical to surviving certain protozoan and
bacterial infections.
In addition to restraining hemorrhage, fibrin(ogen) also functions protectively by limiting
the growth and/or dissemination of certain pathogens. After inoculation with the gram-
positive bacteria L. monocytogenes or Staphylococcus aureus (4, 5), but not after inoculation
with T. gondii (3), fibrinogen-deficient mice exhibit greatly increased pathogen burden. One
potential explanation is that physical entrapment of bacteria by fibrin may limit their
capacity to disseminate (6, 7). Additionally, fibrin(ogen) may facilitate bacterial clearance
by phagocytes: fibrinogen is a ligand for CD11b/CD18 and CD11c/CD18, signal-
transducing integrins expressed by leukocytes (8, 9), and studies of gene-targeted
fibrinogen-mutant mice suggest that fibrin(ogen) stimulates inflammation leading to the
recruitment and activation of leukocytes (5, 10, 11). Many bacteria produce factors that bind
to fibrin and/or regulate fibrin levels, presumably as a means to counter fibrin-mediated host
defense mechanisms (12, 13).
Given the protective and pathological potential of fibrin during infection, the development
of therapeutics that safely suppress septic coagulopathy while maintaining protective
hemostasis and other critical elements of fibrin-dependent host defense may require a
thorough understanding of hemostatic pathway regulation during infection. Already, a great
deal is known about the regulation of hemostasis during vascular trauma and thrombosis.
Procoagulant pathways initiate fibrin formation by stimulating production of thrombin, a
protease that cleaves soluble fibrinogen, prompting its polymerization and deposition as
insoluble fibrin. TF plays a prominent role in the initiation of vascular procoagulant
pathways (14). TF is expressed primarily by extravascular cells, whereas the proteases that
generate thrombin circulate in plasma as inactive precursors. This physical segregation
usually ensures that this “extrinsic” coagulation pathway is only activated in response to
breaches of vascular integrity. However, procoagulant pathways also may be activated by
inflammation-induced upregulation of TF on cells within the vasculature (2, 14), or by TF-
independent pathways, such as the FXI-dependent “intrinsic” coagulation pathway (12, 15).
Regardless of the initiating mechanisms, procoagulant pathways all culminate in the
formation of a prothrombinase (PT) complex that produces thrombin, the protease that
cleaves fibrinogen, thereby prompting its polymerization and deposition as fibrin. These
procoagulant activities are limited by multiple anticoagulant mechanisms, including TF
pathway inhibitor, anti-thrombin, and activated protein C (APC) (2, 16). Once formed, fibrin
levels are regulated by plasmin, a fibrin-degrading protease derived from plasminogen upon
its proteolytic activation by plasminogen activators (PA). Fibrinolysis is negatively
regulated by multiple factors including PAI-1 (17), an inflammation-inducible PA antagonist
whose levels increase during sepsis (18), and TAFI, an enzyme that indirectly suppresses
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plasminogen activation by modifying fibrin in a manner that reduces its affinity for
plasminogen and PA (19, 20).
Therapeutic targeting of TF and other elements of the extrinsic coagulation pathway can
lessen pathology and improve survival in animal models of bacterial sepsis (2, 14, 21, 22).
However, many human clinical trials for sepsis have failed to demonstrate that treatment
with anticoagulants can significantly improve survival (1, 2). Only one anticoagulant,
recombinant human APC (rhAPC), has been licensed for the treatment of severe sepsis (16,
23), and the overall therapeutic benefit of rhAPC has been questioned, in part because
serious bleeding is a significant complication in patients treated with this potent
anticoagulant (24). Therapeutic strategies based on partial anticoagulation, for example via
depletion of FXI (25), or based on augmentation of fibrinolysis, for example by
antagonizing PAI-1 and/or TAFI (18, 26, 27) are under investigation.
Gram-negative bacteria are a common cause of sepsis and sepsis-associated coagulopathy
(1, 28). Animal models of sepsis commonly employ bolus injections of the gram-negative
bacterium E. coli or its endotoxin as challenge. Typically, these models lead to intoxication,
rather than colonization and sustained infection (29–31). Host defense roles for coagulation
and fibrin deposition may be dispensable in intoxication models of gram-negative sepsis, but
critical in settings of sustained infection. Yersinia enterocolitica is a gram-negative
bacterium that establishes sustained infections in mice that must be cleared by a robust host
response (32, 33). Transmission of Y. enterocolitica to humans typically follows the
ingestion of contaminated food, water and milk (34). The resulting yersiniosis typically
manifests as a self-limiting enterocolitis, however, Y. enterocolitica also can cause
extraintestinal disorders, including sepsis (34, 35). Moreover, transfusion-associated septic
yersiniosis, which results from the growth of Y. enterocolitica in refrigerated blood, has
greater than 35% case fatality rates (34, 36–38). Here, we demonstrate that fibrin performs
multiple protective functions in the C57BL/6 mouse model of yersiniosis, including the
induction of cytokine and chemokine expression, activation of neutrophil recruitment, and
restraint of bacterial burden. Investigations of the mechanisms regulating the deposition of
protective fibrin revealed critical roles for TF but not FXI. Our studies also revealed synergy
in the anti-fibrinolytic functions of PAI-1 and TAFI. We discuss the relevance of these
findings to the development of sepsis therapeutics that aim to limit coagulopathy without
preventing the deposition of protective fibrin.
Materials and Methods
Mice
C57BL/6 wild type and PAI-1-deficient mice were obtained from Jackson Laboratory (Bar
Harbor, ME). C57BL/6 fibrinogen-deficient mice (39), FXI-deficient mice (40), and TAFI-
deficient mice (41) were generously supplied by Jay L. Degen, David Gailani and Edward F.
Plow, respectively. PAI-1/TAFI-deficient mice were generated at Trudeau Institute. Nigel
Mackman supplied C57BL/6 mice with very low levels of TF activity (low-TF mice). These
mice lack expression of mouse TF due to its inactivation by gene targeting and instead
express a human TF transgene, which imparts low-level TF activity (mTF−/−hTF+) (42).
Low-TF mice were compared with littermates heterozygous for mouse TF and expressing
human TF (mTF+/−hTF+). When littermate fibrinogen-deficient mice, FXI-deficient mice, or
TF transgenic mice were compared, they were co-housed with controls and the investigators
were blinded with regard to the animals’ genotypes. All experimental mice were bred in a
specific pathogen-free facility at Trudeau Institute. They were matched for age and sex, and
infected between 6 and 10 weeks of age. Where indicated, mice were anticoagulated
pharmacologically by supplementing drinking water with 2 mg/liter coumadin [3-(α-
acetonylbenzyl)-4-hydroxycoumarin; Sigma] beginning 3 days prior to infection or 1 day
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after infection with replenishment every 48 hours; this anticoagulant regimen reduces fibrin
deposition in mice during infection (4). All animal studies were conducted in accordance
with Trudeau Institute Animal Care and Use Committee guidelines.
Bacterial infection
Y. enterocolitica strain WA (serotype O:8) (32) was obtained from ATCC (#27729). After
growth to early log phase at 26°C in brain heart infusion broth (BHI; Difco laboratories,
Detroit, MI), bacteria were resuspended in BHI supplemented with 20% glycerol and stocks
were stored as single use aliquots at −70°C. Preliminary studies established that the
intravenous dose that caused half the mice to succumb to infection (LD50) was 5×104 colony
forming units (CFU). For experimental infections, frozen bacteria were diluted with saline to
the desired dose and administered in a 100 μl volume. The number of bacteria in the
inoculating dose was confirmed by plating on BHI agar.
Measurements of survival and bacterial burden
Mice were monitored daily. Unresponsive or recumbent animals were considered moribund
and euthanized. For measurement of bacterial burden, fluids and tissues were collected after
mice were euthanized by carbon dioxide narcosis. Bacterial burden was measured by
homogenizing tissues in saline, plating serial dilutions on BHI agar, incubating overnight at
26°C, and counting CFU.
Measurements of blood parameters, fibrin deposition, and hepatic PT and PA activity
Blood was collected by cardiac puncture from mice that received 500 U heparin
intravenously just prior to euthanasia. After dilution in saline containing 5 mM EDTA,
hematocrits and platelet numbers were measured using a Coulter Counter (Beckman).
Plasma levels of D-dimer were measured by ELISA (Diagnostica Stago) and reported as
fold-change relative to the average value measured in naïve C57BL/6 mice. Levels of fibrin
in liver tissue were quantified as described (3) and scored positive when above the limit of
detection (15 ng/mg of tissue). In brief, fibrin was extracted from homogenized liver tissue
and quantified by Western blot using fibrin-specific mAb 350 (American Diagnostica, Inc.);
the standard curve was prepared from mouse fibrinogen treated with thrombin (3). Levels of
PT and PA activity in liver tissue were quantified in situ using validated assays (43). In
brief, fresh frozen livers were sectioned (7 μm) mounted onto slides, and overlaid with
human prothrombin (Enzyme Research Laboratories). After incubation at 37°C, thrombin
levels were quantified using Spectrozyme TH (American Diagnostica) and normalized to the
area of the tissue section. Purified human alpha-thrombin (Enzyme Research Laboratories)
was used as standard. PA assays were performed similarly to PT assays, with the following
modifications: prothrombin was replaced by human Glu-plasminogen (Enzyme Research
Laboratories), the standard curve was prepared using purified human plasmin (Enzyme
Research Laboratories), and plasmin levels were measured using Spectrozyme PL
(American Diagnostica). PT and PA activity are presented as fold-change relative to the
levels measured in tissue samples collected from naïve mice.
Measurements of immune parameters
To assess responses in the peritoneal cavity, mice were euthanized and peritoneal exudate
fluid was harvested by lavage using 5 ml saline. Neutrophil percentages were determined by
inspection of Wright-Giemsa-stained cytospin smears. IL-6 and monocyte chemoattractant
protein-1 (MCP-1) levels were determined by ELISA using OptEIA kits (BD Biosciences).
Levels of hepatic mRNA encoding IL-1β, IL-6, IL-10, IFN-γ, and TNF-α were measured by
real-time PCR, normalized to levels of GAPDH, and expressed as log10 fold-change relative
to levels measured in uninfected control mice (3).
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Tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and
stained with hematoxylin and eosin. The number of large pathological foci in each section
was counted (i.e. areas with large numbers of infiltrating cells accompanied by evidence of
anoxic or necrotic hepatocytes and/or bacterial colonization). Representative
photomicrographs depict ×200 magnification.
Statistics
Statistical analyses were performed using the computer program Prism 4.0 (GraphPad
Software, Inc.). Survival data were analyzed by log rank tests. Cytokines, cell numbers, and
CFU data were analyzed by parametric tests; Student’s t test or one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison test, unless CFU levels fell below the
limit of detection (135 CFU), in which case mice were assigned a value of 100 CFU and
data were analyzed by nonparametric tests. Box and whisker plots depict the minimum,
maximum, median and 25th and 75th percentile.
Results
Fibrinogen impacts peritoneal inflammatory responses during yersiniosis
Prior reports indicate fibrinogen can impact peritoneal inflammation after inoculation with
gram-positive bacteria (5). To assess roles for fibrinogen during gram-negative infection, we
infected fibrinogen-deficient and littermate control fibrinogen-heterozygous mice with Y.
enterocolitica serotype O:8 strain WA (32). Specifically, we examined peritoneal exudate
fluid collected 3 hours after intraperitoneal inoculation with 1×103 CFU Y. enterocolitica.
The exudates obtained from fibrinogen-deficient mice, as compared with those collected
from control fibrinogen-heterozygous mice, contained significantly reduced levels of the
inflammatory cytokine IL-6 and chemokine MCP-1 (Figure 1A; p=0.006 and 0.0006,
respectively). Fibrinogen-deficient mice also displayed significantly reduced numbers of
neutrophils in exudate fluid (Figure 1B; p=0.0005).
At 3 hours after inoculation with 1×103 CFU Y. enterocolitica, we could not detect bacteria
in the peritoneal fluid. After increasing the challenge dose to 1×106 CFU, we observed
significantly higher bacterial burden in fibrinogen-deficient mice as compared with
littermate control fibrinogen-heterozygous mice (Figure 1C, p=0.0008). Fibrinogen-
deficiency also significantly increased the number of bacteria that reached the liver at 3
hours after intraperitoneal inoculation with 1×106 CFU Y. enterocolitica (Figure 1C,
p=0.01). These data indicate that fibrin(ogen) impacts inflammation and host defense against
bacteria at early times after intraperitoneal inoculation with Y. enterocolitica.
Fibrin protects against peritoneal yersiniosis
Y. enterocolitica serotype O:8 is virulent in humans (34–38) and mice (32, 33). To
investigate whether fibrinogen impacts susceptibility to Y. enterocolitica infection, we
inoculated fibrinogen-deficient mice with a dose of Y. enterocolitica that is sublethal for
wild type mice. We observed that fibrinogen-deficient mice succumbed after inoculation
with 0.05 LD50 Y. enterocolitica (2.5×103 CFU), whereas all fibrinogen-heterozygous
littermate mice survived. The difference in survival was highly significant (p<0.0001).
Measurements of bacterial burden 5 days after Y. enterocolitica inoculation revealed
significantly higher numbers of CFU in the livers and spleens of fibrinogen-deficient mice,
as compared with control mice (Figure 2B).
Since fibrinogen-deficient mice lack both fibrinogen and fibrin, next we treated wild type
mice with coumadin, a pharmaceutical used clinically for long-term anticoagulation.
Luo et al. Page 5













Coumadin-treated mice possess normal levels of circulating fibrinogen but generate far less
fibrin (4). Like fibrinogen-deficient mice, coumadin-treated mice acutely succumbed to
intraperitoneal inoculation with 2.5×103 CFU Y. enterocolitica (Figure 2C). Coumadin
treatment also significantly increased bacterial burden in livers and spleens collected 5 days
after initiating the infection (Figure 2D). The similar phenotypes observed in fibrinogen-
deficient and coumadin-treated mice following intraperitoneal inoculation with Y.
enterocolitica strongly suggest that fibrin functions protectively during gram-negative
peritonitis.
Fibrin functions protectively during systemic yersiniosis
Prior reports suggest fibrin may physically trap bacteria, thereby limiting dissemination
from the peritoneal cavity (6, 7) and liver vasculature (44). To investigate whether fibrin
functions protectively beyond the peritoneal cavity during gram-negative bacterial infection,
we inoculated mice intravenously with Y. enterocolitica. Fibrinogen-heterozygous mice
largely survived intravenous inoculation with 1×103 CFU Y. enterocolitica whereas
fibrinogen-deficient mice displayed significantly reduced survival (Figure 3A; p<0.0001).
Moreover, 5 days after intravenous inoculation with 1×103 CFU Y. enterocolitica,
fibrinogen-deficient mice displayed significantly increased bacterial burden in liver and
spleen (Figure 3B). As for intraperitoneal inoculation, coumadin treatment also increased
susceptibility to yersiniosis following intravenous inoculation with Y. enterocolitica: in
comparison with untreated control mice, coumadin-treated mice exhibited significantly
decreased survival (Figure 3C, p<0.0001) and increased bacterial burden (Figure 3D).
Coumadin treatment also led to significantly decreased survival when the initiation of
treatment was delayed until one day after the initiation of infection (Figure 3C, p=0.002).
Notably, coumadin treatment did not alter the levels of plasma fibrinogen measured at day 5
after infection (data not shown). Together, these data suggest that fibrin not only activates
peritoneal inflammation and antibacterial defense but also contributes to antibacterial host
defense mechanisms that operate beyond the peritoneal cavity. Interestingly, fibrinogen-
deficient mice did not exhibit decreased survival when inoculated orally with Y.
enterocolitica (1×108 CFU intragastrically; fibrinogen-heterozygous 25% survival,
fibrinogen-deficient 29% survival, p>0.05), suggesting that fibrin is critical for systemic but
not mucosal host defense against this gram-negative bacterium.
Kinetics of fibrin deposition during sublethal yersiniosis
Given that fibrin-deficient mice displayed increased hepatic bacterial burden after
inoculation with Y. enterocolitica, we investigated whether hepatic fibrin was detectable
during the course of yersiniosis in wild type mice. Specifically, we inoculated wild-type
mice intravenously with 1×103 CFU Y. enterocolitica and then analyzed bacterial burden
and fibrin levels on days 1, 3, 5, 7, 10 and 14 after infection. We detected hepatic bacteria in
most mice on days 1, 3, 5, 7 and 10, with the greatest burden apparent on day 5 (Figure 4A).
Hepatic fibrin levels in mice infected with Y. enterocolitica were lower than those reported
previously for mice infected with Listeria or Toxoplasma (3, 4). While we could only detect
fibrin in a subset of infected animals, nevertheless, it was apparent that fibrin deposition
peaked on day 5, thus coinciding with the time of maximal bacterial burden (Figure 4B).
Notably, yersiniosis also was characterized by significant thrombocytopenia (decreased
platelet counts; Figure 4C) and anemia (decreased hematocrits; Figure 4D), suggesting
systemic activation of coagulation and sublethal bleeding, respectively. Consistent with peak
fibrin deposition on day 5, procoagulant activity also peaked at that time, as measured by in
situ measurements of hepatic PT activity (Figure 4E). Interestingly, hepatic PA activity
peaked at day 3 and declined significantly by day 5, perhaps explaining the increased fibrin
deposition on day 5 (Figure 4F). Levels of D-dimer, a systemic measure of fibrinolysis, did
not rise significantly above baseline at any time point (data not shown) but levels of hepatic
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mRNA encoding PAI-1 and TAFI, two inhibitors of fibrinolysis, increased over the course
of yersiniosis (Figure 4G and 4H), potentially explaining the decreased hepatic PA activity
at the time of peak fibrin deposition. These data establish that hemostatic pathways become
activated during sublethal yersiniosis in wild type mice over the same period during which
fibrin(ogen)-deficient mice succumb to infection.
Critical roles for TF, but not FXI, during yersiniosis
Given evidence of coagulation during sublethal yersiniosis (i.e. increased hepatic PT activity
and fibrin deposition), we investigated roles for key elements of the extrinsic and intrinsic
coagulation pathways. Tissue factor is the primary initiator of the extrinsic coagulation
pathway. While fully TF-deficient mice (i.e. mTF−/− mice) die in utero, TF function can be
studied in vivo using mTF−/− mice expressing a human TF transgene (i.e. mTF−/−hTF+
mice) (42). Consistent with prior studies (42, 43), we observed that liver tissue from these
low-TF mice contained significantly reduced levels of baseline hepatic PT activity (Figure
5A, p<0.0001). In contrast, baseline PT activity was similar in wild type mice and mice
deficient in FXI, a key component of the intrinsic coagulation pathway (Figure 5B).
By day 5 after intravenous inoculation with 1×103 CFU Y. enterocolitica, levels of PT
activity in low-TF mice had increased substantially but still remained significantly below
those measured in control mice (p<0.0001). Like fibrin(ogen)-deficient mice (Figure 3), the
infected low-TF mice also displayed significantly increased bacterial burden (Figure 5C;
p=0.003) and reduced survival (Figure 5D, p=0.002) as compared to littermate control
mTF+/−hTF+ mice. In contrast, the FXI-deficient mice did not exhibit increased bacterial
burden or reduced survival (Figures 5C, 5D). These data suggest that the TF-dependent
extrinsic coagulation pathway plays a dominant role in the regulation of host-protective
fibrin production during sublethal yersiniosis.
Synergistic protective roles for PAI-1 and TAFI during yersiniosis
Levels of hepatic mRNA encoding PAI-1 and TAFI increased over the course of yersiniosis,
peaking on days 5 and 7, respectively (Figure 4G and 4H). To investigate the importance of
PAI-1 and TAFI expression, and to measure their capacity to regulate PA activity in this
model, we infected gene-targeted mice lacking expression of PAI-1, TAFI, or both PAI-1
and TAFI. Basal levels of hepatic PA activity were similar in all these mice and all the mice
displayed similarly elevated PA activity at day 3 after intravenous inoculation with 1×103
CFU Y. enterocolitica (Figure 5E). Consistent with our prior kinetic analysis (Figure 4F),
PA activity decreased in wild type mice by day 5. In contrast, PA activity remained elevated
on day 5 in mice deficient in PAI-1, TAFI or both PAI-1 and TAFI, and these mice all
exhibited significantly increased levels of hepatic PA activity when compared with wild
type mice (Figure 5E, all p<0.01). Levels of plasma D-dimer, a systemic marker of
fibrinolysis, did not increase significantly in wild type mice or TAFI-deficient mice infected
with Y. enterocolitica. However, mice deficient in PAI-1 displayed significantly increased
D-dimer levels on day 3 after inoculation with Y. enterocolitica, and PAI-1/TAFI-deficient
mice displayed significantly increased D-dimer levels on both days 3 and 5 (Figure 5F).
In comparison with wild type mice, the bacterial burden in PAI-1-deficient mice increased
significantly on both days 3 and 5 after inoculation with Y. enterocolitica, and the PAI-1/
TAFI-deficient mice displayed even greater burden (Figure 5G). TAFI-deficient mice
exhibited bacterial burden similar to wild type mice on days 3 or 5 but their splenic burden
increased significantly on day 7 (Figure 5G and data not shown). In comparison with wild
type mice, the TAFI-, PAI-1- and PAI-1/TAFI-deficient mice all exhibited significantly
reduced survival following inoculation with Y. enterocolitica; PAI-1/TAFI-deficient
displayed the greatest susceptibility, followed sequentially by PAI-1-deficient mice and
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TAFI-deficient mice (Figure 5H). Together, these findings suggest that PAI-1 and TAFI
perform complementary functions that synergistically regulate fibrinolysis during
yersiniosis.
Fibrin(ogen), TF, PAI-1 and TAFI impact inflammation and pathology during yersiniosis
After intravenous inoculation with Y. enterocolitica, fibrinogen-deficient mice, low-TF mice
and PAI-1/TAFI-deficient mice all displayed evidence of increased hepatic inflammation.
Specifically, they displayed significantly increased levels of hepatic mRNA encoding IL-1β,
IL-6, IL-10, IFNγ, and TNFα when compared with their respective control mice (Figure 6
and data not shown). These observations must be interpreted with caution since the
increased inflammation could be a consequence of the increased bacterial burden in these
mice (Figures 3 and 5).
After infection with Y. enterocolitica, fibrinogen-deficient mice, PAI-1/TAFI-deficient mice
and low-TF mice all displayed significantly greater reductions in blood hematocrits and
circulating platelet numbers when compared with control mice (Figure 6). While this
hematological data was suggestive of bleeding, histological observations rarely revealed
evidence of hemorrhage in fibrin-deficient mice and stool samples rarely tested positive for
hemoglobin. This finding contrasts sharply with our prior studies of toxoplasmosis and
listeriosis in fibrin(ogen)-deficient mice, where the exacerbated anemia and
thrombocytopenia were accompanied by frank hemorrhage (3, 4).
Although fibrin did not appear to protect from hepatic hemorrhage during yersiniosis it did,
nonetheless, dramatically impact liver histopathology (Figure 7). Wild type mice infected
with Y. enterocolitica displayed very limited hepatic damage and small, sporadic sites of
inflammation. Mice deficient in either PAI-1 or TAFI likewise displayed small foci of
mixed leukocytes similar to those observed in wild type mice. In striking contrast,
fibrinogen-deficient mice, low-TF mice, and PAI-1/TAFI-deficient mice all displayed
significantly exacerbated histopathology, evidenced by large bacterial colonies and
extensive areas of tissue damage characterized diffuse leukocyte infiltration and
hepatocellular necrosis.
Discussion
This report demonstrates that fibrinogen-deficient mice and wild type mice treated with
coumadin succumb to doses of Y. enterocolitica that control mice survive. Moreover,
fibrinogen-deficient mice, low-TF mice and PAI-1/TAFI-deficient mice all exhibit similar
decreases in survival, increases in bacterial burden, and exacerbations of anemia and hepatic
histopathology after inoculation with Y. enterocolitica. These observations provide strong
complementary evidence that fibrin performs critical protective functions in this model of
sublethal gram-negative infection. This study focused on fibrin but we certainly
acknowledge that other elements of hemostatic pathways also impact inflammation and
infection (2, 12, 13, 45).
Our demonstration that fibrin can function protectively during gram-negative infection,
coupled with the wealth of evidence that excessive coagulation can function pathologically
during sepsis (2), suggests that appropriate regulation of fibrin levels will be critical for
surviving certain septic infections. The up-regulation of coagulation during infection is
likely initiated, at least in part, by host recognition of microbial components, leading to the
activation of innate immunity, secretion of inflammatory cytokines, and consequent up-
regulation of TF expression, thus activating the extrinsic pathway of coagulation (2, 12, 14).
Our data suggest that antagonistic targeting of the TF-dependent extrinsic pathway reduces
fibrin levels to below those required for host defense against yersiniosis. Full antagonism of
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other critical components of the extrinsic pathway, such as factor Xa or thrombin, would be
predicted to similarly compromise fibrin-mediated protection. Thus, our studies caution that
supra-physiologic dosing of rhAPC, the only approved therapeutic for severe sepsis, may
suppress fibrin-mediated host defense. Likewise, excessive activation of fibrinolysis, as we
accomplished by simultaneously inactivating PAI-1 and TAFI, may reduce fibrin to sub-
protective levels.
While our observations indicate that the TF is critical for host defense against Y.
enterocolitica, antagonism of TF and other elements of the extrinsic coagulation pathway
improves survival in mice and primates inoculated with another gram-negative bacterium, E.
coli, or its endotoxin (i.e. lipopolysaccharide) (2, 14, 21, 22). Thus, coagulation appears to
be required for effective host defense against some, but not all, gram-negative bacteria. This
observation may help to explain why anticoagulant therapies that show great promise in
preclinical models of E. coli sepsis often do not translate to human efficacy in clinical trials
(1, 2, 29–31). One notable distinction between E. coli and Y. enterocolitica is that the latter
produces a relatively non-inflammatory form of lipopolysaccharide when grown at 37°C
(46). Additionally, host defense against Y. enterocolitica is critically dependent upon T cells
and IFNγ (33), whereas T cells and IFNγ actually contribute to pathology during E. coli
infection (47, 48). A better understanding of the roles for coagulation during host defense
and a full delineation of the pathogens that do and do not require protective coagulant
responses may allow selective targeting of anticoagulant therapies to patients for whom the
benefits of anticoagulation outweigh the risks of suppressing fibrin-mediated host defense.
Another approach to preventing coagulopathy while maintaining fibrin-mediated host
defense may be to target elements of DIC-related hemostatic pathways whose full
antagonism does not deplete fibrin levels to below those required for protection. Our studies
indicate that targeting TF overly compromises host defense against sublethal yersiniosis,
whereas targeting FXI has no impact on survival, burden or morbidity. FXI-deficiency
improves survival in the mouse model of lethal bacterial sepsis induced by cecal ligation and
puncture (25), but does not improve survival during lethal Y. enterocolitica infection (data
not shown), presumably because something other than FXI-mediated DIC is the primary
cause of death during lethal yersiniosis. Together, these observations suggest that FXI does
not contribute to antibacterial host defense but sometimes contributes to septic
coagulopathy. As such, we believe that FXI and other components of the intrinsic pathway
deserve further investigation as therapeutics for septic DIC.
To our knowledge this is the first report demonstrating that TAFI-deficiency can impair
survival in mice infected with pathogens. We cannot exclude the possibility that fibrinolysis-
independent impacts of TAFI play a role (20, 49), but our data decisively demonstrate
increased fibrinolysis in TAFI-deficient mice infected with Y. enterocolitica (Figure 5E and
5F). Renckens et al observed a transient increase in bacterial burden in TAFI-deficient mice
infected with E. coli but, in striking contrast to our results, this did not impair survival and,
rather, appeared to protect against liver injury (50). Again, this apparent discrepancy may
relate to intrinsic differences between the pathogenesis of E. coli and Y. enterocolitica
infections. We also demonstrated that PAI-1-deficiency decreases survival and increases
bacterial burden during yersiniosis. Renckens et al reported analogous observations for
PAI-1-deficient mice infected with Klebsiella pneumoniae (51). As for TAFI, we cannot
exclude the possibility that fibrinolysis-independent impacts of PAI-1 play a role (17), but
our data decisively demonstrate increased fibrinolysis in TAFI-deficient mice infected with
Y. enterocolitica (Figure 5E and 5F). Altogether, these studies indicate that full antagonism
of either TAFI or PAI-1 can impair host defense against gram-negative bacteria, but leave
open the possibility that therapeutics targeting TAFI or PAI-1 may suppress coagulopathy
without compromising host defense in certain settings (e.g. E. coli infection).
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One of the most striking findings in this study was the synergy achieved by simultaneously
antagonizing both TAFI and PAI-1. In comparison with mice deficient in either PAI-1 or
TAFI, mice deficient in both PAI-1 and TAFI displayed significantly increased levels of
plasma D-dimer and significantly exacerbated liver pathology. To our knowledge, this
synergy has not been demonstrated previously in vivo, although it was postulated based
upon in vitro models of thrombolysis (52). This synergy suggests that the consequences of
targeting either PAI-1 or TAFI may be heavily influenced by the levels of the non-targeted
factor. That is, the impact of PAI-1 antagonism may be far more pronounced in settings (e.g.
certain tissues or disease states) where TAFI levels are relatively low.
Multiple mechanisms appear to contribute to fibrin-mediated host defense against
yersioniosis. The increased bacterial burden observed in fibrin-deficient mice infected with
Y. enterocolitica resembles that previously reported by our laboratory (4), and others (5),
after inoculating fibrin(ogen)-deficient mice and fibrinogen-mutant mice with gram-positive
bacteria. Thus, it seems that one fundamental function of fibrin is to limit bacterial growth.
We are not aware of studies describing fibrin-binding proteins in Y. enterocolitica, but many
other bacterial species possess diverse mechanisms for binding fibrin(ogen) and/or
activating fibrinolysis (12, 13). It seems likely that bacteria have acquired the ability to
interact with fibrin, at least in part, as a means to counter fibrin-mediated host defense.
While previously it has been suggested that fibrin may physically prevent bacterial
dissemination during peritoneal infections (6, 7), we observed that fibrin also impacts
bacterial burden after intravenous delivery of Y. enterocolitica. One possible explanation is
that fibrin may contribute to microvessel thrombosis within infected liver tissue, thereby
physically preventing dissemination of bacteria from the bloodstream (44, 53).
Alternatively, fibrin may restrain bacterial growth by facilitating the recruitment and
activation of bactericidal phagocytes within infected tissues. Prior studies reported that
fibrinogen activates peritoneal macrophages and neutrophils in mice inoculated with
lipopolysaccharide (10) and gram-positive bacteria (5). Consistent with those reports, this
study demonstrates that fibrinogen facilitates the accumulation of peritoneal neutrophils
after inoculation with Y. enterocolitica (Figure 1). And consistent with prior studies of
sterile peritonitis (10), this report demonstrates that fibrinogen stimulates production of
MCP-1 and IL-6 at early time points after inoculation with Y. enterocolitica. These impacts
may be mediated by CD11b/CD18 and/or TLR4, since these receptors reportedly activate
cytokine and chemokine production via fibrin(ogen)-mediated mechanisms (11, 54–56).
MCP-1 recruits monocytes, and IL-6 is a pleiotropic cytokine known to promote fibrin
deposition (57) and participate in host defense against Y. enterocolitica (58). Since
monocytes express CD11b/CD18 and ligation of CD11b/CD18 by fibrin(ogen) activates
peritoneal phagocytes (5), it is easily conceivable that fibrin acts as an inducible matrix
supporting feedback amplification of signals leading to the activation and accumulation of
antibacterial phagocytes at sites of inflammation.
Our findings suggest relatively minor roles for the hemostatic functions of fibrin during host
defense against gram-negative bacterial infection. Anemia, evidenced by reduced
hematocrits, is evident in wild-type mice inoculated with sublethal doses of Y. enterocolitica
(Figure 4). Fibrin-deficient mice show exacerbated anemia (Figure 6) and begin to succumb
to yersiniosis at day 5 of the infection, which coincides with the time of maximal anemia in
wild type mice (Figure 3). We likewise observed exacerbated anemia in our prior studies of
fibrin-deficient mice inoculated with protozoa and gram-positive bacteria (3, 4). In those
studies, we observed unmistakable evidence of frank hemorrhage in the livers of fibrinogen-
deficient mice, leading us to conclude that the anemia reflected bleeding. In contrast, we
observed relatively little evidence of hepatic hemorrhage in fibrin-deficient mice during
yersiniosis, despite a high bacterial burden (Figure 7). Thus, the extent to which fibrin
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provides critical hemostatic protection during infection appears to vary, presumably
reflecting the extent to which different pathogens predispose to hemorrhagic pathology.
Although hemorrhage was uncommon in the hepatic lesions of Y. enterocolitica-infected
fibrin-deficient mice, we nevertheless observed significant differences in the overall
appearance of these lesions in comparison with those observed in fibrin-sufficient mice.
Specifically, fibrin-deficient mice exhibited severe hepatocellular necrosis. We also
observed increased levels of inflammatory cytokines in the liver at later stages of septic
yersiniosis in fibrin-deficient mice. Increased cytokine production also is evident in
fibrin(ogen)-deficient mice during septic listeriosis (4). Many mechanisms could potentially
account for the exacerbation of hepatic pathology and inflammation in the absence of fibrin,
however, we believe it most likely to be a consequence of the increased bacterial burden in
fibrin-deficient mice.
Septic coagulopathy can be caused by many different types of microorganisms (28, 59).
Ideally, identical therapeutics and dosing regimen would be appropriate for all patients
presenting with septic coagulopathy, regardless of the causative microbe. The development
of universal therapies may be confounded by the fact that microorganisms interact with
components of the coagulation and fibrinolytic pathways in diverse and unique ways (12,
13). Moreover, the antibacterial functions of fibrin-mediated host defense may be
dispensable in septic patients when suitable antibiotics are prescribed, but may be critical in
cases where the causative pathogens are insensitive to antibiotics. Likewise, fibrin-mediated
hemostatic defense may only be critical for some pathogens. The rational design of
universally effective sepsis therapeutics, if feasible, should be aided by a precise
understanding of the regulation of host-protective fibrin in diverse models of infection.
In summary, this report demonstrates that fibrin performs multiple host defense functions
during yersiniosis. In this model of gram-negative infection, fibrin suppresses bacterial
burden, influences inflammation and pathology, and can be critical for survival. The balance
of coagulation and fibrinolysis dictate levels of protective fibrin during Y. enterocolitica
infection. Thus, the mouse model of yersiniosis provides a means to investigate the relative
importance of specific hemostatic pathway elements during fibrin-mediated host defense.
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Figure 1. Fibrin(ogen) regulates inflammation during peritoneal yersiniosis
Measurements of (A) inflammatory mediators and (B) cells in peritoneal exudate fluid
collected from fibrinogen-deficient mice (Fib KO; solid bars) and littermate control
fibrinogen-heterozygous mice (Fib Het; open bars) at 3 hours after intraperitoneal
inoculation with 1×103 CFU Y. enterocolitica. In comparison with control mice, fibrinogen-
deficient mice exhibited decreased levels of IL-6 (p=0.006) and MCP-1 protein (p=0.0006),
and decreased numbers of neutrophils (p=0.0005). (C) Bacterial burden at 3 hours after
intraperitoneal inoculation with 1×106 CFU Y. enterocolitica. In comparison with control
fibrinogen-heterozygous mice, fibrinogen-deficient mice exhibited significantly increased
bacterial burden in peritoneal fluid (p=0.0008) and liver tissue (p=0.01). Similar results were
observed in two independent experiments. Statistical significance was analyzed by student’s
t test (n=5–8 mice per group).
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Figure 2. Fibrin protects against peritoneal yersiniosis
(A) Survival and (B) bacterial burden for fibrinogen-deficient mice (Fib KO) and littermate
control fibrinogen-heterozygous mice (Fib Het) after intraperitoneal inoculation with
2.5×103 CFU Y. enterocolitica. In comparison with control mice, fibrinogen-deficient mice
exhibited significantly reduced survival (p<0.0001; n=9 mice/group) and significantly
increased hepatic and splenic bacterial burden at day 5 after infection (n=6–7 mice/group).
(C) Survival and (D) bacterial burden of wild type coumadin-treated (Coum) and control
C57BL/6 mice after intraperitoneal inoculation with 2.5×103 CFU Y. enterocolitica. In
comparison with control mice, coumadin-treated mice exhibited significantly reduced
survival (p<0.05; n=5 mice/group) and significantly increased hepatic and splenic bacterial
burden at day 5 after infection (n=5 mice/group). Similar results were observed in two
independent experiments.
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Figure 3. Fibrin functions protectively during systemic yersiniosis
(A) Survival and (B) bacterial burden for fibrinogen-deficient (Fib KO) mice and littermate
control fibrinogen-heterozygous (Fib Het) mice after intravenous inoculation with 1×103
CFU Y. enterocolitica. In comparison with control mice, fibrinogen-deficient mice exhibited
significantly reduced survival (p<0.0001; n=6–7 mice/group) and significantly increased
hepatic and splenic bacterial burden at day 5 after infection (n=5–8 mice/group). (C)
Survival and (D) bacterial burden of coumadin-treated (Coum) and control wild-type mice
after intravenous inoculation with 1×103 CFU Y. enterocolitica. In comparison with control
mice, mice treated with coumadin beginning on day −3 (d−3) or day +1 (d+1) relative to
infection exhibited significantly reduced survival (n=5 mice/group for coumadin and n=10
mice/group for control). The survival of the day −3 and day +1 groups did not differ
significantly from each other. The day −3 treatment led to significantly increased hepatic
and splenic bacterial burden at day 5 after infection (n=5 mice/group). Similar results were
observed in two independent experiments.
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Figure 4. Hepatic fibrin deposition accompanies the acute phase of sublethal yersiniosis
Wild-type C57BL/6 mice were inoculated intravenously with 1×103 CFU Y. enterocolitica.
On the indicated days, mice were assayed for hepatic bacterial burden (A), hepatic fibrin
deposition (B), blood platelet numbers (C), blood hematocrits (D), hepatic PT activity (E),
hepatic PA activity (F), hepatic PAI-1 mRNA (G) and hepatic TAFI mRNA (H). The data
are compiled from two independent experiments and depict the mean ± standard deviation of
9–10 mice per time point, except for day 1, which only had 5 mice. The dashed line
indicates the level of detection for bacterial CFU. Statistics were performed using ANOVA
followed by Dunnett’s multiple-comparison test, except that the non-parametric Kruskal-
Wallis with Dunn’s post-test was used to evaluate bacterial burden (* p<0.05, ** p<0.01,
*** p<0.001).
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Figure 5. Protective roles for TF, PAI-1 and TAFI, but not FXI, during yersiniosis
Hepatic PT activity was quantified in mTF−/−hTF+ low-TF mice and mTF+/−hTF+ littermate
control mice (A), and in FXI-deficient (FXI KO) mice and littermate control FXI-
heterozygous (Het) and wild type (WT) mice (B). Significantly decreased basal PT activity
was measured in naïve low-TF mice (p<0.0001) but not in FXI-deficient mice (n=4–6 mice/
group). Significantly decreased PT activity also was measured in low-TF mice, but not FXI-
deficient mice, 5 days after intravenous inoculation with 1×103 CFU Y. enterocolitica
(p<0.0001, n=5–7 mice/group). Hepatic bacterial burden (C) and survival (D) also was
impacted significantly by TF-deficiency (p=0.003 and p=0.002, respectively) but not FXI-
deficiency (n=5–7 mice/group). Hepatic PA activity (E) plasma D-dimer (F) hepatic
bacterial burden (G) and survival were quantified in PAI-1-deficient (PAI-1 KO) mice,
TAFI-deficient (TAFI KO) mice, PAI-1/TAFI-deficient (P/T KO) mice and control wild
type C57BL/6 mice after intravenous inoculation with 1×103 CFU Y. enterocolitica. For E–
G, n=17–20 mice/group for naïve (“n”) and 7–10 mice/group for day 3 and day 5 (* p<0.05,
** p<0.01 in comparison to wild type C57BL/6 mice by ANOVA). The mice all displayed
similar levels of basal PA activity and similarly increased PA activity at day 3 after
inoculation with Y. enterocolitica. On day 5, PA activity increased significantly in PAI-1-
deficient mice, TAFI-deficient mice, and PAI-1/TAFI-deficient mice, as compared with wild
type control mice. Plasma D-dimer levels were similar at baseline in PAI-1-deficient, TAFI-
deficient, PAI-1/TAFI-deficient and wild type C57BL/6 mice but increased significantly in
PAI-1/TAFI-deficient mice on days 3 and 5. Hepatic bacterial burden increased significantly
in PAI-1-deficient mice and PAI-1/TAFI-deficient mice. In comparison with wild type mice
(n=30), significantly reduced survival was observed for PAI-1-deficient mice (p<0.0001;
n=19), TAFI-deficient mice (p=0.008; n=20) and PAI-1/TAFI-deficient mice (p<0.001;
n=5).
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Figure 6. Deficiencies in fibrinogen, TF and PAI-1/TAFI similarly impact inflammation, anemia
and thrombocytopenia during yersiniosis
Fibrinogen-deficient (Fib KO) mice and littermate control fibrinogen-heterozygous (Fib
Het) mice (A, D, G, J, M; n=7–13 mice/group), mTF−/−hTF+ low-TF mice and mTF+/−hTF+
littermate control mice (B, E, H, K, N; n=5–7 mice/group), or wild type C57BL/6 mice and
PAI-1/TAFI deficient (PAI-1/TAFI KO) mice (C, F, I, L, O; n=6–20 mice/group) were
intravenously inoculated with 1×103 CFU Y. enterocolitica, analyzed 3 or 5 days later, and
compared to uninfected naïve mice. Hepatic mRNA encoding IL-6 (A–C), IFNγ (D–F) and
IL-10 (G–I) were measured by quantitative PCR. Blood hematocrits (J–L) and platelet
numbers (M–O) were measured by Coulter Counter. The asterisks depict ANOVA
comparisons of naïve to day 3 and day 5 for each strain of mice (*p<0.05, **p<0.01,
***p<0.001). The numbers depict p values for student’s t test comparisons of day 3 and day
5 samples across the indicated strains of mice. In comparison with infected control mice,
infected fibrinogen-deficient mice, low-TF mice, and PAI-1/TAFI-deficient mice all showed
significantly increased levels of IL-6, IL-10 and IFNγ and significantly decreased
hematocrits and platelet numbers.
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Figure 7. Deficiencies in fibrinogen, TF and PAI-1/TAFI similarly impact hepatic histopathology
during yersiniosis
Hematoxylin and eosin staining of representative liver samples collected from the mice
described in Figure 6. In comparison with naive C57BL/6 mice (A), C57BL/6 mice infected
with Y. enterocolitica (B) displayed sporadic small sites of inflammation. The
histopathology of infected mTF+/−hTF+ mice (C) PAI-1-deficient mice (E) and TAFI-
deficient mice (F) resembled that of the infected C57BL/6 control mice. In contrast, the
mTF−/−hTF+ low-TF mice (D), PAI-1/TAFI-deficient mice (G) and fibrinogen-deficient
mice (H) exhibited large foci characterized by mixed inflammatory infiltrates with extensive
tissue necrosis (asterisks), and bacterial colonization (arrowheads). Histopathological
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scoring (I) revealed significantly greater numbers of large foci in liver samples collected
from the infected mTF−/−hTF+ low-TF mice (p=0.02), PAI-1/TAFI-deficient mice (p=0.03)
and fibrinogen-deficient mice (p=0.03), as compared with infected wild type C57BL/6 mice.
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